Drug
Isosorbide clinical trials
- studies test it
- 17
- open now
- 2
- in phase 3
- 1
- first study started
- 2005
Keep track of what changes. Save the Isosorbide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 4 |
| 2009 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 14
- Phase 3
- 1
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 5
Ascenta Therapeutics (9) · University of Michigan Rogel Cancer Center (2) · Alvogen Korea (1) · National Cancer Institute (NCI) (1) · Vanderbilt University (1) · Lunan Better Pharmaceutical Co., LTD. (1) · AbClon (1) · University of Alabama at Birmingham (1)
Often tested with
Tested in the same studies.
Anti-CD19 CAR T Cells AT101 (14) · Gossypol-acetic acid (14) · Gossypol acetic acid (14) · Docetaxel (2) · Omega-N-Methylarginine (1) · Bradykinin (1) · Sildenafil (1) · Prednisone (1)
Studies
Open first, then newest update. How each study uses Isosorbide is read from its arms, and is right about nine times in ten.
Testing it · 17
- Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's DiseaseNot yet recruitingPhase 2/3Lunan Better Pharmaceutical Co., LTD.NCT06765993Written as Isosorbide oral solution
- Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaRecruitingPhase 1/2AbClonNCT05338931Written as AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
- Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal CancerCompletedPhase 2University of Michigan Rogel Cancer CenterNCT01633541Written as AT-101
- A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and NeckTerminatedPhase 2University of Michigan Rogel Cancer CenterNCT01285635Written as AT-101
- Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace TabletsCompletedPhase 4Alvogen KoreaNCT02718846Written as Isobide
- Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung CancerWithdrawnPhase 1University of Alabama at BirminghamNCT00934076Written as Tarceva plus AT-101
- R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00666666Written as AT-101
- Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3CompletedNot applicableVanderbilt UniversityNCT00685945Written as Isosorbide + L-NMMA + bradykinin
- An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction CancerTerminatedPhase 1/2Ascenta TherapeuticsNCT00561197Written as AT-101
- Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell MalignanciesCompletedPhase 2Ascenta TherapeuticsNCT00275431Written as AT-101
- Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPCCompletedPhase 1/2Ascenta TherapeuticsNCT00286793Written as AT-101
- A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)CompletedPhase 2Ascenta TherapeuticsNCT00571675Written as AT-101, prednisone and docetaxel
- A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung CancerCompletedPhase 2Ascenta TherapeuticsNCT00544960Written as AT-101 and docetaxel
- Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's LymphomaCompletedPhase 2Ascenta TherapeuticsNCT00440388Written as AT-101
- A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate CancerCompletedPhase 1/2Ascenta TherapeuticsNCT00286806Written as AT-101
- Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung CancerCompletedPhase 1/2Ascenta TherapeuticsNCT00397293Written as AT-101
- Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic LeukemiaCompletedPhase 2Ascenta TherapeuticsNCT00286780Written as AT-101
Codes
What other systems call Isosorbide · ClinicalTrials.gg INT007697
- MeSH (NLM) D007547IsosorbideConfirmed NLM, Wikidata
- UNII (FDA) WXR179L51SISOSORBIDEConfirmed FDA, NLM, Wikidata
- RxNorm 6057Confirmed FDA, Wikidata
- Wikidata Q1243800isosorbideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C60773IsosorbideOne source FDA
- DrugBank DB09401One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D007547 | Isosorbide | Confirmed NLM, Wikidata |
| UNII (FDA) | WXR179L51S | ISOSORBIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 6057 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1243800 | isosorbide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C60773 | Isosorbide | One source FDA |
| DrugBank | DB09401 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.